Evidence map›Paper›PMID 42363965›Full record

ArticleEuropean radiology2026

Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)?

Kumaresan Sandrasegaran, Amar S Shah, Cole P Thompson, Channa R Jayasekera, Elizabeth J Carey, Ayana Jain, Aubrey N Silva, Suhaas R Bonkur, Anshuman J Panda, Sudhakar K Venkatesh and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kumaresan SandrasegaranDepartment of Radiology, Mayo Clinic, Scottsdale, AZ, USA. Sandrasegaran.Kumaresan@mayo.edu.ORCID http://orcid.org/0000-0002-0325-2372
Amar S ShahDepartment of Radiology, Washington University, St. Louis, MO, USA.
Cole P ThompsonDepartment of Radiology, Mayo Clinic, Scottsdale, AZ, USA.
Channa R JayasekeraDepartment of Hepatology/GI, Mayo Clinic, Scottsdale, AZ, USA.
Elizabeth J CareyDepartment of Hepatology/GI, Mayo Clinic, Scottsdale, AZ, USA.
Ayana JainDepartment of Radiology, Mayo Clinic, Scottsdale, AZ, USA.
Aubrey N SilvaDepartment of Radiology, Mayo Clinic, Scottsdale, AZ, USA.
Suhaas R BonkurDepartment of Radiology, Mayo Clinic, Scottsdale, AZ, USA.
Anshuman J PandaDepartment of Radiology, Mayo Clinic, Scottsdale, AZ, USA.
Sudhakar K VenkateshDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Alvin C SilvaDepartment of Radiology, Mayo Clinic, Scottsdale, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo determine if functional information from gadoxetate disodium-enhanced MRI is useful in assessing prognosis in primary sclerosing cholangitis (PSC). MATERIALS AND

methodsIn this retrospective case-controlled study, 73 patients with PSC and gadoxetate-enhanced MRI were enrolled. Four radiologists independently assessed qualitative and quantitative MRI features. The value of these features in predicting adverse events (liver-related death, hepatic decompensation from grade III/IV hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis as well as need for liver transplantation) within 2 years of MRI were compared with recognized radiological scores as well as clinical scoring systems (Mayo Risk Score, Amsterdam-Oxford model and UK PSC score), using multivariate logistic regression and receiver operating characteristic curve analysis.

resultsThe cohort consisted of 42 males and 31 females, with a mean age of 41.9 years. In the 2-year period after MRI, 26 patients had adverse events, 8 had liver transplantation, and 6 died. On multivariate analysis, only Mayo Risk Score (p = 0.001) and relative enhancement of proximal extrahepatic bile ducts (REPD) (p = 0.035) were significant in predicting adverse outcomes. REPD of < 4.64 had 70% sensitivity and 63% specificity in such an event. The only variable that significantly predicted liver transplantation was ANALI non-gadolinium score (p = 0.0003). ANALI score of > 3 had a sensitivity of 87.5% and specificity of 74.2% for predicting the need for liver transplantation.

conclusionsRelative enhancement ratio of extrahepatic bile ducts at 20 min after gadoxetate disodium provides useful information in predicting adverse events in PSC patients and is complementary or superior to the currently used clinical scoring systems. KEY POINTS: Question Can functional hepatic and biliary parameters, obtained from gadoxetate-enhanced MRI, be useful in predicting adverse events in patients with primary sclerosing cholangitis? Findings The relative enhancement of proximal bile ducts (REPD) was useful in predicting adverse events and the need for liver transplantation within 2 years of MRI. Clinical relevance ANALI score predicts need for liver transplantation and may be included in MRI reports of patients with PSC. REPD is more difficult to measure on a routine clinical basis and may only be useful in drug trials.

Indexed as

Gadoxetate disodiumLiverMRIPrimary sclerosing cholangitisPrognosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.